Introducing Fortifeye Fit Pro

2 months ago

Elevating Fitness Performance and RecoveryOCALA, FL / ACCESSWIRE / January 30, 2024 / Fortifeye Fit Pro, the latest innovation from…

American Family Care Climbs the Prestigious Entrepreneur Franchise 500 List

2 months ago

Nation's Largest Urgent Care Provider Ranks at Top of Health Services CategoryBIRMINGHAM, AL / ACCESSWIRE / January 30, 2024 /…

HCA Healthcare Reports Fourth Quarter 2023 Results and Provides 2024 Guidance

2 months ago

Bill Rutherford to Retire and Mike Marks to Become CFONASHVILLE, Tenn.--(BUSINESS WIRE)--HCA Healthcare, Inc. (NYSE: HCA) today announced financial and…

From the Margins: Gilead’s Book Uniquely Captures What It’s Like To Be Marginalized by Disease

2 months ago

NORTHAMPTON, MA / ACCESSWIRE / January 30, 2024 / Gilead Sciences - The personal journeys of six people in the…

Physicians Shift 2024 Tech Investments to Robust Practice Management Platforms With AI, Analytics and Value-Based Care Support Tools, Black Book Survey

2 months ago

Surveyed providers endorse NextGen Healthcare PM Solutions to meet the challenges surrounding increasing administrative burden, shrinking labor pools, telehealth, and…

CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Topical Gel for the Treatment of Acne Vulgaris Now Available in the U.S.

2 months ago

LAVAL, QC / ACCESSWIRE / January 30, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its dermatology business, Ortho Dermatologics,…

Izotropic Receives Response From U.S. FDA

2 months ago

Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the…

Zomedica to Participate in the Lytham Partners 2024 Investor Select Conference

2 months ago

ANN ARBOR, MI / ACCESSWIRE / January 30, 2024 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary…

Kura Oncology Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

2 months ago

– No differentiation syndrome events reported – – 100% CR rate with 7+3 in newly diagnosed NPM1-m and KMT2A-r AML…